Journal of Antimicrobial Chemotherapy

Effect of general practice characteristics and antibiotic prescribing on *Escherichia coli* antibiotic non-susceptibility in the West Midlands region of England: a 4 year ecological study

Dean Ironmonger¹*, Obaghe Edeghere¹, Neville Q. Verlander², Savita Gossain³, Susan Hopkins^{4,5}, Bridget Hilton¹ and Peter M. Hawkey^{3,6}

 ¹Field Epidemiology Service, Public Health England, Birmingham, UK; ²Statistics, Modelling and Economics Department, Public Health England, London, UK; ³Public Health Laboratory, Public Health England, Heart of England NHS Foundation Trust, Birmingham, UK;
 ⁴Department of Infectious Diseases and Microbiology, Royal Free London NHS Foundation Trust, London, UK; ⁵Healthcare Associated Infections Surveillance, National Infection Service, Public Health England, London NW9 5EQ, UK; ⁶Institute of Microbiology and Infection, Biosciences, University of Birmingham, Birmingham, UK

*Corresponding author. Tel: +44-7711-028483; Fax: +44-1212362428; E-mail: dean.ironmonger@phe.gov.uk

Received 27 September 2017; accepted 7 November 2017

Objectives: To assess the effect of general practice characteristics and antibiotic prescribing on the number of non-susceptible *Escherichia coli* isolated from urine specimens submitted from community settings, we undertook an ecological study of the general practice population in the West Midlands.

Methods: Descriptive analysis and multilevel modelling of temporal trends in antibiotic prescribing and non-susceptibility of *E. coli* urine isolates to a range of antibiotics prescribed in the community over a 4 year period.

Results: Nine of the 16 antibiotic prescribing/non-susceptibility combinations demonstrated a significant statistical linear correlation with non-susceptibility either for prescribing in a quarter or for prescribing within the previous 12 months. The magnitude of the effect varied, from a 0.3% increase in the odds of non-susceptibility to ampicillin/amoxicillin (when prescribing ampicillin/amoxicillin) to a 6.3% increase in the odds of non-susceptibility to nitrofurantoin (when prescribing nitrofurantoin) for an increase of 50 DDDs per 1000 practice population within a quarter (equivalent to \sim 10 courses of antibiotics). In all 16 models, single-handed general practices were shown to have a significant association with increased numbers of non-susceptible *E. coli* urine isolates (adjusted ORs 1.083–1.657). Increased prescribing of ampicillin/amoxicillin in winter periods was associated with increased non-susceptibility of *E. coli* isolated from urine specimens.

Conclusions: Small increases in antibiotic prescribing in individual general practices reduce the number of susceptible bacteria in the practice population. To maintain the effectiveness of available treatment, antibiotic stewardship should be encouraged and supported within each practice.

Introduction

Antimicrobial resistance (AMR) is a considerable threat to public health and the use of antibiotics has been cited as the single most important factor leading to AMR.¹ In 2014 in England, 74% of antibiotic prescribing occurred in general practice.² Antibiotic prescribing in the community is associated with the development of AMR;^{3,4} however, some community prescribers are sceptical that reduction in their antibiotic prescribing will reduce the levels of AMR in their practice population.⁵ Other factors such as the practice location, length of appointment,⁶ social deprivation⁷ and single-handed practices⁸ have been shown to be associated with increased antibiotic prescribing in the UK.

The Chief Medical Officer for England in her 2011 annual report promoted the use of antibiotic stewardship as a measure to control the development and spread of AMR;⁹ however, a study in 2014 reported that PHE clinical prescribing guidance has not reduced prescribing in the community.¹⁰

Urinary tract infections (UTIs), in particular those caused by *Escherichia coli*, were the focus of this study because UTIs are one of the most common conditions diagnosed in community settings in Europe and are an important clinical indication of prescribing in primary care,¹¹ with *E. coli* being the most common cause of UTIs in both primary and secondary care.¹²

A systematic review of studies reporting on the association between antibiotic prescribing and resistance reported that the inability to measure the time between prescribing and detection of resistance, control for practice/population characteristics or examine co-selection (use of one antibiotic leading to resistance to another antibiotic) has been a limiting factor when interpreting results.³

To address some of the gaps in previous studies, we undertook an ecological study to examine the relationship between prescribing antibiotics commonly used in general practice and nonsusceptibility of *E. coli* isolates from urine samples taken in general practices in the West Midlands region of England over a 4 year period.

Methods

Ethics

PHE has approval under Section 251 of the NHS Act 2006 (originally enacted under Section 60 of the Health and Social Care Act 2001) to process confidential patient information for public health surveillance (see https://www.legislation.gov.uk/ukpga/2006/41/section/251). However, the AMR surveillance data extracted for this study did not include patient identifiers and general practice identifiers were anonymized when creating the models.

Setting/population

In 2012, there were 950 general practices with 3635 general practitioners (GPs) serving a population of 5.8 million registered patients in the West Midlands region.¹³ During 2010–14, there were 15 diagnostic microbiology laboratories serving both community-based healthcare centres and hospitals.

Data sources

Antibiotic prescribing data on items dispensed in each general practice during the period 2010–14 were obtained from NHS Digital (previously known as the Health and Social Care Information Centre).¹⁴ Antibiotic prescribing data are expressed as DDDs per 1000 general practice population.

Data on antibiotic non-susceptibility for *E. coli* isolates from urine specimens submitted from general practices were obtained from the PHE Second Generation Surveillance System, previously known as the AmSurv system.¹⁵ To detect emerging non-susceptibility, we de-duplicated the dataset by removing only duplicate *E. coli* reports from each patient having exactly matching antibiotic susceptibility results within the same year. Nine of the 15 laboratories were reporting data regularly to the Second Generation Surveillance System/AmSurv at the start of our study period in 2010, and complete coverage of all 15 laboratories was achieved in 2012.

Non-susceptibility to an antibiotic was defined as test results with a 'resistant' (R) or 'intermediate' (I) designation. The antibiotics included in the study are detailed in Table 1.

Data on general practice characteristics were obtained from the NHS Business Services Authority (http://www.nhsbsa.nhs.uk/). This included data on the total practice population, proportion of the practice population <15 and ≥65 years old, and ratio of females to males in the practice population. The number of GPs within each practice was obtained from NHS Digital, with single-handed practices defined as those practices with only one registered GP.¹⁶

We measured socio-economic deprivation using data from the English Index of Multiple Deprivation 2010.¹⁷ A deprivation index was assigned to each general practice based on the deprivation index assigned to the Local Authority (English administrative area) in which the practice was located.

The general practices were categorized as 'urban' or 'rural' based on whether the majority of the population in the Local Authority in which the practice is situated live in a rural or urban setting.¹⁸

Table 1. Antibiotic combinations evaluated to measure commonly associated resistance mechanisms found in *E. coli* and enable comparison with international studies

-		
E. coli non-susceptibility	Prescribed antibiotic	Statistical model no.
Ampicillin/amoxicillin	ampicillin/amoxicillin	2
	co-amoxiclav	1
	fluoroquinolones	3
Cefalexin	cephalosporins	10
	fluoroquinolones	11
	trimethoprim	16
	nitrofurantoin	12
Co-amoxiclav	co-amoxiclav	9
	ampicillin/amoxicillin	4
Ciprofloxacin	ampicillin/amoxicillin	6
	fluoroquinolones	8
	co-amoxiclav	5
	cefalexin	7
Trimethoprim	trimethoprim	15
Nitrofurantoin	nitrofurantoin	14
	cefalexin	13

Descriptive analysis

Seasons were defined as spring (March–May), summer (June–August), autumn (September–November) and winter (December–February). We calculated seasonal total DDD prescribing quantities and DDDs/1000 practice population for the period March 2010–February 2014. These were compared with non-susceptibility proportions for *E. coli* urinary isolates against the six antibiotics selected for analysis to describe prescribing and non-susceptibility trends during the study period.

Statistical analysis

Sixteen separate datasets were created. Each dataset consisted of data on all reported *E. coli* isolates non-susceptible to one of the six selected antibiotics by practice, alongside matching practice-prescribing data for the same antibiotic or another commonly prescribed antibiotic that may select non-susceptibility (Table 1).

Antibiotic combinations were selected based on biological plausibility of an exposure/non-susceptibility relationship and to enable comparisons with other international studies.³ For each combination, seasonal quarterly trends in non-susceptibility of *E. coli* isolates for each general practice from 1 March 2010 to 28 February 2014 were compared with trends in antibiotic prescribing data in the same quarter and previous quarters (up to four lagged quarters).

National community prescribing guidance recommends course lengths of between 3 and 7 days depending on the antibiotic and the clinical presentation.¹⁹ We therefore set a prescribing unit within the statistical models of 50 DDDs, which represents ~10 prescriptions, taking an average of 5 days for each course.

General practice characteristics were included in the statistical models as potential explanatory variables (Table 2).

Multilevel mixed-effects generalized linear models, using a binomial distribution for the outcome, were developed to examine the relationship between antibiotic use and *E. coli* non-susceptibility. Each statistical model (one for each prescribing/non-susceptibility combination) consisted of the number of *E. coli* isolates non-susceptible by general practice as the outcome variable, number tested as the denominator and the various explanatory variables, including antibiotic prescribing in the current and lagged

E. coli non-susceptible (%)

11.8

182

6.9

52.1

34.8

2.7

 Table 2. Explanatory variables included in the multilevel mixed-effects

 statistical model

Table 3. Percentage of antibiotic tests and non-susceptibility, March2010–February 2014

E. coli tested (%)

77.2

83.4

85.1

99.8

99.9

88

Antibiotic

Cefalexin

Ciprofloxacin

Co-amoxiclav

Nitrofurantoin

Trimethoprim

Ampicillin/amoxicillin

Variables	West Midlands mean or percentage (if applicable)
General practice characteristics	
general practice patient list size	6252
registered patient gender ratio (female/male)	0.98
proportion of registered patients <15 years old	18.21%
proportion of registered patients aged \geq 65 years old	16.15%
practices with one registered GP	15%
number of registered patients per GP	1700.31
location deprivation index (IMD2010)	28.14
rural practice location	27%
Time variables seasonal quarter (Mar–May, Jun–Aug, Sep–Nov, Dec–Feb) time variable for study period	

prescribing quarters described above, which formed the fixed-effect portion of the models. A composite group variable was created using general practice and Local Authority area to form a second-level random intercept to allow modelling of variability between these hierarchical populations as random effects. Likelihood ratio testing was used to determine significance and $P \leq 0.05$ was considered statistically significant. Adjusted ORs were used as a measure of association.

Cubic functions of all continuous explanatory variables were constructed and then subsequently tested for linearity via a stepwise iterative process. Significant non-linear variables were retained and tested to determine if they were still significant when inserted into the model together. When satisfied that any remaining non-linear terms were still significant when tested together in the model, the significance of the linear covariates was tested. All lagged prescribing quarters were included in each of the statistical models; however, as prescribing data prior to 2010 were not available, to increase the number of complete observations the DDD/1000 practice population variable with the greatest lag was removed if it was found to be not statistically significant, and was not a substantial confounder (i.e. its removal did not lead to a >10% change in the ORs of the linear variables). The model building process was then repeated with the increased number of comparable observations.

All other explanatory variables were retained in a linear or non-linear form, depending on which form was found to best fit the data within each model (see the Supplementary data available at JAC Online).

All statistical analyses were performed using STATA v13 (StataCorp, USA).

Results

During the study period, there were 313 085 *E. coli* reports from urine specimens submitted by West Midland GPs. These represented 247971 de-duplicated laboratory reports of *E. coli*, from 181764 patients, submitted by 911 of 948 (96%) general practices prescribing antibiotics in the West Midlands.

The proportion of <i>E. coli</i> isolates tested against the selected
The proportion of L. con isolates tested against the selected
antibiotics and the proportion reported as non-susceptible during
מו ונטוטנוכא מו זע נו זב או טאטו נוטו ז באטו נפע עא דוטו -אטגנפאנוטנפ עעו וו זע

antibiotics and the proportion reported as non-susceptible during the study period are shown in Table 3. Antibiotic prescribing data were available for 948 of the 950 practices registered in the West Midlands during the study

period. The quantity of antibiotic prescribing varied widely across general practices. In 2013, the 5th and 95th percentiles for total antibiotics prescribed by individual West Midland general practices were 4431 DDDs/1000 population and 10076 DDDs/1000 population. In 2013, a total of 45 million antibiotic DDDs were prescribed in the West Midlands. Amongst the antibiotics included in the study, ampicillin/amoxicillin was the most commonly prescribed in 2013 with 13.6 million DDDs, followed by co-amoxiclav with 2.9 million DDDs and trimethoprim with 2.8 million DDDs.

Fifteen percent (141 of 948) of general practices were singlehanded (Table 2), and 82% (116 of 141) of these were designated as being in rural locations. When comparing single-handed GPs as a group, the prescribing rate was consistently higher throughout the study period than the group consisting of non-single-handed GP practices (Figure 1).

Increased non-susceptibility to ampicillin/amoxicillin was observed in *E. coli* urine isolates in the winter periods, which mirrored observed winter peaks in prescribing of ampicillin/amoxicillin (Figure 2). Seasonal changes in antibiotic prescribing and nonsusceptibility was not observed for other antibiotics included in the study.

Nine of the 16 multilevel mixed-effects statistical models showed a statistically significant linear relationship between *E. coli* non-susceptibility and the prescription of defined antibiotics during the same seasonal quarter or prescribing within the previous 12 months. Three of the remaining models showed statistically significant non-linear relationships for some of the seasonal quarters, and four models had no statistical associations between the prescribed antibiotic and non-susceptibility (please see the Supplementary data available at *JAC* Online for complete modelling results).

Ampicillin/amoxicillin was the only antibiotic for which the odds of increased *E. coli* non-susceptibility was associated with an increase in prescribing within the same quarter, when prescribing ampicillin/amoxicillin and co-amoxiclav (OR 1.003, 95% CI 1.001–1.006 and OR 1.006, 95% CI 1.002–1.009, respectively) (Table 4).

There was also an association between prescribing in previous quarters and increased non-susceptibility of *E. coli* to co-amoxiclav




Figure 1. Seasonal trends in total antibiotic prescribing rates by practices with a single GP and those with multiple GPs, West Midlands, March 2010– November 2013.




Figure 2. Ampicillin/amoxicillin prescribing and non-susceptibility of E. coli urine isolates, West Midlands, 2010–13.

(when prescribing ampicillin/amoxicillin), ciprofloxacin (when prescribing fluoroquinolones), nitrofurantoin (when prescribing cefalexin and nitrofurantoin) and trimethoprim (when prescribing trimethoprim) (Table 4).

The magnitude of the statistical associations varied. In Model 2, for every increase of 50 DDDs per 1000 population of ampicillin within the same quarter we found an increase in the odds of ampicillin/amoxicillin non-susceptibility of 0.3% (95% CI 0.2%–0.6%, P = 0.001). In Model 14, for every increase of 50 DDDs per 1000 population of nitrofurantoin within the previous quarter we found an increase in the odds of nitrofurantoin non-susceptibility of 6.3% (95% CI 1.3%–11.5%, P = 0.013).

There was a significant negative association in the same quarter with non-susceptibility to co-amoxiclav when prescribing ampicillin/amoxicillin, ciprofloxacin when prescribing co-amoxiclav, and trimethoprim when prescribing trimethoprim, and in the same quarter and in the previous 12 months for nitrofurantoin when prescribing nitrofurantoin (Table 4), indicating increased prescribing in those periods is associated with lower numbers of non-susceptible *E. coli*.

A statistically significant positive association was found between *E. coli* non-susceptibility and single-handed practices in all 16 prescribing/non-susceptibility statistical models (Table 5), with a single-handed practice associated with increased

Table 4. Adjusted significant linear	associations betw	veen antibiotic prescribing	and non-susceptibility	in E. coli, by current	(0) or lagged
(negative) quarter					

Model no.	Antibiotic non- susceptibility	Antibiotic prescribed	Prescribing period	Adjusted OR (50 DDD unit/1000 population)	95% CI (lower)	95% CI (upper)	P value
1	ampicillin/amoxicillin	co-amoxiclav	quarter 0	1.006	1.002	1.009	0.003
2	ampicillin/amoxicillin	ampicillin/amoxicillin	quarter 0	1.003	1.001	1.006	0.001
4	co-amoxiclav	ampicillin/amoxicillin	quarter 0	0.994	0.991	0.998	0.003
			quarter -3	1.006	1.002	1.009	0.004
			quarter —4	1.006	1.002	1.009	0.002
5	ciprofloxacin	co-amoxiclav	quarter 0	0.986	0.975	0.997	0.015
8	ciprofloxacin	fluoroquinolones	quarter -4	1.033	1.003	1.066	0.034
9	co-amoxiclav	co-amoxiclav	quarter —3	1.017	1.009	1.026	< 0.001
13	nitrofurantoin	cefalexin	quarter —3	1.041	1.009	1.075	0.013
14	nitrofurantoin	nitrofurantoin	quarter 0	0.955	0.914	0.997	0.036
			quarter —1	1.063	1.013	1.115	0.013
			guarter —4	0.791	0.703	0.890	< 0.001
15	trimethoprim	trimethoprim	quarter 0	0.988	0.978	0.999	0.031
	,	,	quarter —1	1.016	1.004	1.028	0.008
			quarter —2	1.018	1.006	1.030	0.003
			, quarter −4	1.016	1.005	1.026	0.005

Table 5. Adjusted OR between single GP practices and antibiotic non-susceptibility of E. coli from urine isolates

Model no.	Antibiotic non-susceptibility	Antibiotic prescribed	Single GP (adjusted OR)	95% CI (lower)	95% CI (upper)	P value
1	ampicillin/amoxicillin	co-amoxiclav	1.097	1.027	1.171	0.006
2	ampicillin/amoxicillin	ampicillin/amoxicillin	1.083	1.014	1.156	0.018
3	ampicillin/amoxicillin	fluoroquinolones	1.095	1.024	1.170	0.008
4	co-amoxiclav	ampicillin/amoxicillin	1.361	1.148	1.614	< 0.001
5	ciprofloxacin	co-amoxiclav	1.458	1.267	1.676	< 0.001
6	ciprofloxacin	ampicillin/amoxicillin	1.448	1.258	1.666	< 0.001
7	ciprofloxacin	cefalexin	1.370	1.180	1.592	< 0.001
8	ciprofloxacin	fluoroquinolones	1.371	1.182	1.590	< 0.001
9	co-amoxiclav	co-amoxiclav	1.398	1.171	1.669	< 0.001
10	cefalexin	cephalosporin	1.528	1.322	1.767	< 0.001
11	cefalexin	fluoroquinolones	1.534	1.337	1.759	< 0.001
12	cefalexin	nitrofurantoin	1.534	1.340	1.756	< 0.001
13	nitrofurantoin	cefalexin	1.606	1.304	1.979	< 0.001
14	nitrofurantoin	nitrofurantoin	1.657	1.352	2.031	< 0.001
15	trimethoprim	trimethoprim	1.110	1.026	1.201	0.009
16	cefalexin	trimethoprim	1.603	1.395	1.841	< 0.001

numbers of non-susceptible *E. coli* urine isolates (adjusted ORs 1.083–1.657).

Discussion

Our study showed that small increases in antibiotic prescribing by general practices in the West Midlands for a range of antibiotics increased the odds that *E. coli* UTI isolates from the practice population would be non-susceptible to one or more antibiotics.

Although an ecological study across a large regional population, our findings of an association between ampicillin/amoxicillin

non-susceptibility in *E. coli* and prescribing levels during the same period are similar to those from patient-level studies in England in 2005 and Wales in 2007.^{20,21} The Welsh study also supports our findings of no statistical association between ampicillin/amoxicillin non-susceptibility and prescribing of ampicillin/amoxicillin 12 months prior to the susceptibility tests.²¹

A 2007 study of a large portion of the general practice population in Wales found a statistically significant decrease in ampicillin resistance of 1.03% for every decrease of 50 amoxicillin items dispensed per 1000 patients per annum and a decrease in trimethoprim resistance of 1.08% for every decrease of 20 trimethoprim items dispensed per 1000 patients per annum,²² which supports our findings, only in the opposite direction as we measured the effect on non-susceptibility by small increases in antibiotic prescribing.

The immediate effect described of increased E. coli nonsusceptibility to ampicillin/amoxicillin with increased prescribing of β-lactam antibiotics (Models 1 and 2) may be due to the selection and rapid multiplication of TEM β -lactamase-producing strains²³ (Table 4). It is therefore plausible that the selection of these strains would have a negative association with co-amoxiclav, as observed in Model 4, as this antibiotic remains active against common TEM β-lactamases. The successful E. coli urinary pathogenic clonal group ST131 is associated with combined non-susceptibility to β -lactam antibiotics and fluoroquinolones²⁴ and therefore the successful action of co-amoxiclav against these strains may reduce the population non-susceptible to ciprofloxacin, as observed in Model 5. The negative association with non-susceptibility to coamoxiclav (prescribing ampicillin/amoxicillin) and trimethoprim (prescribing trimethoprim) in the immediate guarter is reversed in previous prescribing quarters with a positive association, suggesting sufficient time had elapsed for a previously susceptible population to acquire resistance.

Nitrofurantoin remains active against MDR *E. coli*, which may explain the negative association with non-susceptibility and increased prescribing of nitrofurantoin in the same quarter. Non-susceptibility to nitrofurantoin is conferred by mutation, and we observe increased odds of non-susceptibility when prescribing nitrofurantoin in the previous quarter. A study from Sweden in 2013²⁵ suggests that the establishment of *E. coli* clones non-susceptible to nitrofurantoin is unlikely due to the severe fitness cost imposed by the required mutation. This may explain the negative association we observe in prescribing nitrofurantoin 12 months previously (Model 14).

To our knowledge, this is the first study to show that singlehanded practices are associated with higher levels of antibiotic non-susceptibility. A systematic review measuring the effectiveness of single-handed practices suggested that the observed higher general prescribing rates by these practices might be due to higher workloads, shorter appointment times and the lack of opportunity to discuss prescribing protocols with colleagues.²⁶ Although we report that 15% of practices in the West Midlands were single-handed, there has been a move towards group practices in England; however, in many parts of Europe single-handed practices still predominate.²⁶

We report an observed temporal relationship between prescribing ampicillin/amoxicillin and non-susceptibility to this antibiotic in *E. coli* urine isolates, with peaks in the winter months (Figure 2). In a study in the USA in 2012 similar seasonal relationships were demonstrated for a number of combinations of prescribed antibiotics and resistance, including a correlation of prescribing aminopenicillins (lagged by 1 month) and resistance in all *E. coli* isolates.²⁷ Ampicillin/amoxicillin prescribing represented 30% of the total quantity of antibiotics prescribed in the West Midlands in 2013. In the UK, amoxicillin is not first-line treatment for UTI, but it is first-line treatment for many community respiratory infections.¹⁹ It is therefore plausible that the winter peaks in prescribing for respiratory conditions is selecting non-susceptibility in urine isolates. A recent UK study found that most general practices overprescribe for respiratory conditions.²⁸ A randomized controlled trial in 2005 showed use of narrow-spectrum antibiotics rather than amoxicillin resulted in comparable clinical outcomes among hospitalized patients with community-acquired pneumonia.²⁹ Our findings suggest this approach may also result in reduced numbers of non-susceptible *E. coli* in the population.

This is a retrospective ecological study and therefore is not able to draw inferences about individual risk of AMR. Significant statistical associations in these types of studies should be interpreted as only suggestive as they do not necessarily imply cause–effect relationships. Whilst this is a limitation, it was noted in a large review published in 2014 of individual patient and ecological studies that antibiotic pressure at the population level may be more important in determining risk of harbouring resistant bacteria in the community.³

DDDs were chosen as the metric for antibiotic prescribing as they are the most commonly applied unit of measurement and are recognized internationally as a benchmarking measure. This metric also allowed comparison with international studies comparing prescribing with antibiotic resistance. However, it is recognized that DDDs do not always accurately reflect prescribing for children or persons with renal impairment.

Multilevel modelling is a strength of this study as it allows random effects in the population to be taken into account whilst adjusting for a number of potential predictor or confounding variables. Following a review of the literature we found only a limited number of studies included practice characteristics, and of these comparable interactions between these variables were either not found²⁰ or were not reported.⁶ A systematic approach of testing potential interactions was considered for our study; however, this would have added >30 pairwise combinations of variables. Therefore, to ensure manageability and aid interpretation we chose to focus on the main effects of the various variables included in this study. We intend to examine potential interactions between practice characteristics in a future study.

Seven of the 16 statistical models developed did not show linear relationships between the prescribed antibiotic and nonsusceptibility in *E. coli* urine isolates. Three of these models, however, did show significant non-linear associations between prescribing and non-susceptibility for some of the seasonal quarters, and this will form part of the new study.

Given the plausibility of bacteria carrying resistance genes to multiple antibiotics, there will be interdependence between some of the antibiotic combinations when measured against the same antibiotic non-susceptibility results. Therefore, with the large amount of testing captured in this study we would expect to encounter a number of type 1 errors for particular antibiotic combinations. A more stringent significance test was considered; however, this was not implemented due to the possibility of increasing the number of false negative associations.

The antibiotic non-susceptibility data were extracted from routine laboratory reporting and therefore are subject to specimen selection bias, as it is likely that urine samples sent for microbiological examination are from patients with treatment failures or those that have complicated and/or severe infections.¹² Notwithstanding this, it is encouraging that a study in Ireland in 2012 of urines taken from all adult patients suspected of having a UTI attending 22 practices found similar antibiotic susceptibility proportions.³⁰ We also found little variation in susceptibility proportions, reported in Table 3, between the de-duplicated data and all *E. coli* reports, providing confidence that this process was not inflating non-susceptibility in our modelling dataset.

As we reported previously, there is variation in antibiotic susceptibility testing methods in West Midland laboratories,¹² and laboratories varied slightly in the antibiotics selected for first-line testing (Table 3). During this period, 13 of the 15 laboratories applied the most recent BSAC or EUCAST MIC breakpoint standards and all laboratories participated in monthly internationally accredited external quality control assessment of susceptibility testing methods.³¹

The West Midlands was the first region in England to implement routine AMR surveillance reporting and achieve complete reporting from local laboratories.¹⁵ Not all laboratories were reporting at the beginning of the study in 2010; however, a comparison of the overall antibiotic susceptibility data from the nine laboratories reporting throughout the study period showed little variation with susceptibility data from all 15 laboratories. Multilevel mixedeffects generalized linear models do allow for missing data; however, although the missing laboratories consisted of a crosssection of laboratory sizes situated in both urban and rural localities, we accept that the missing AMR data in the first period of the study may bias the data.

This large AMR dataset, for the first time (to the best of our knowledge), provides an opportunity to analyse the association between prescribing and resistance in a large English regional population. We are beginning to receive patient-level prescribing data from the community and, therefore, we now have the opportunity to build on this study by further exploring the relationship between prescribing and antibiotic resistance.

In conclusion, our statistical models suggest that small increases in antibiotic prescribing within a general practice increase the number of non-susceptible bacteria isolated in urine samples within the practice population. We have shown that the large volumes of antibiotics likely to have been used in the treatment of respiratory conditions in winter months appear to have an immediate short-term effect of increased antibiotic non-susceptibility in bacteria causing unrelated infections. Prudent prescribing, in line with Royal College of General Practitioners guidance (http://www. rcgp.org.uk/clinical-and-research/toolkits/target-antibiotic-toolkit. aspx) is required by individual general practices, particularly in winter periods, to maintain a population of susceptible bacteria in their local population, thereby preserving the effectiveness of available antibiotics. We have also shown that single-handed GP practices may require additional antibiotic stewardship support and guidance.

Acknowledgements

We thank PHE for their support for this study. We would also wish to acknowledge and thank West Midland diagnostic microbiology laboratories for their continued participation in this voluntary AMR surveillance scheme.

Funding

This work was supported by Public Health England.

Transparency declarations

P. M. H. has received honoraria for developing and delivering educational presentations for Eumedica, Pfizer, Merck, Novartis, MagusCommunications, Wyeth, bioMérieux and Becton-Dickinson, has received research funding from Pfizer and Eumedica, has been a consultant for Pfizer, Novartis, Novacta, Novolytics, Merck, Wyeth and Optimer, and is a director of ModusMedica, a medical education company. All other authors: none to declare.

Supplementary data

The final statistical model results appear as Supplementary data at JAC Online.

References

1 CDC. Antibiotic Resistance Threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.

2 PHE. Antimicrobial Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) 2010 to 2014: Report 2015. 2015. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/477962/ESPAUR _Report_2015.pdf.

3 Bell BG, Schellevis F, Stobberingh E *et al*. A systematic review and metaanalysis of the effects of antibiotic consumption on antibiotic resistance. *BMC Infect Dis* 2014; **14**: 13.

4 Costelloe C, Metcalfe C, Lovering A *et al*. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. *BMJ* 2010; **340**: c2096.

5 Björkman I, Berg J, Viberg N *et al*. Awareness of antibiotic resistance and antibiotic prescribing in UTI treatment: a qualitative study among primary care physicians in Sweden. *Scand J Prim Health Care* 2013; **31**: 50–5.

6 Wang KY, Seed P, Schofield P *et al*. Which practices are high antibiotic prescribers? A cross-sectional analysis. *Br J Gen Pract* 2009; **59**: e315–20.

7 Covvey JR, Johnson BF, Elliott V *et al*. An association between socioeconomic deprivation and primary care antibiotic prescribing in Scotland. *J Antimicrob Chemother* 2014; **69**: 835–41.

8 Wilson RP, Hatcher J, Barton S *et al*. The association of some practice characteristics with antibiotic prescribing. *Pharmacoepidemiol Drug Saf* 1999; **8**: 15–21.

9 Chief Medical Officer. Annual Report of the Chief Medical Officer, Volume Two, 2011: Infections and the Rise of Antimicrobial Resistance. 2013. https:// www.gov.uk/government/uploads/system/uploads/attachment_data/ file/138331/CMO_Annual_Report_Volume_2_2011.pdf.

10 Hawker JI, Smith S, Smith GE *et al.* Trends in antibiotic prescribing in primary care for clinical syndromes subject to national recommendations to reduce antibiotic resistance, UK 1995-2011: analysis of a large database of primary care consultations. *J Antimicrob Chemother* 2014; **69**: 3423–30.

11 Petersen I, Hayward AC. Antibacterial prescribing in primary care. *J Antimicrob Chemother* 2007; **60** Suppl 1: i43–7.

12 Ironmonger D, Edeghere O, Bains A *et al.* Surveillance of antibiotic susceptibility of urinary tract pathogens for a population of 5.6 million over 4 years. *J Antimicrob Chemother* 2015; **70**: 1744–50.

13 NHS Digital. *General and Personal Medical Services, England*—2002-2012. http://content.digital.nhs.uk/catalogue/PUB09536.

14 NHS Digital. *Practice Level Prescribing in England: A Summary*. http://con tent.digital.nhs.uk/gpprescribingdata.

15 Ironmonger D, Edeghere O, Gossain S *et al.* AmWeb: a novel interactive web tool for antimicrobial resistance surveillance, applicable to both community and hospital patients. *J Antimicrob Chemother* 2013; **68**: 2406–13.

16 NHS England Data Catalogue. *ODS - GPs, GP Practices, Nurses and Pharmacies.* 2016. https://data.england.nhs.uk/dataset/ods-gps-gp-practi ces-nurses-and-pharmacies.

17 Department for Communities and Local Goverment. *English Indices of Deprivation*. 2010. https://data.gov.uk/dataset/english_indices_of_deprivation.

18 Department for Environment, Food & Rural Affairs. *Census 2001 Rural Urban Classification for a Range of Geographies*. 2016. https://www.gov.uk/government/statistics/2001-rural-urban-definition-la-classification-and-other-geographies.

19 PHE. Management and Treatment of Common Infections. Antibiotic Guidance for Primary Care: For Consultation and Local Adaptation. 2017. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/524984/Management_of_infection_guidance_for_primary_care_for_con sultation_and_local_adaptation.pdf.

20 Hay AD, Thomas M, Montgomery A *et al*. The relationship between primary care antibiotic prescribing and bacterial resistance in adults in the community: a controlled observational study using individual patient data. *J Antimicrob Chemother* 2005; **56**: 146–53.

21 Hillier S, Roberts Z, Dunstan F *et al.* Prior antibiotics and risk of antibioticresistant community-acquired urinary tract infection: a case-control study. *J Antimicrob Chemother* 2007; **60**: 92–9.

22 Butler CC, Dunstan F, Heginbothom M *et al.* Containing antibiotic resistance: decreased antibiotic-resistant coliform urinary tract infections with reduction in antibiotic prescribing by general practices. *Br J Gen Pract* 2007; **57**: 785–92.

23 Brismar B, Edlund C, Nord CE. Impact of cefpodoxime proxetil and amoxicillin on the normal oral and intestinal microflora. *Eur J Clin Microbiol Infect Dis* 1993; **12**: 714–9.

24 Johnson JR, Johnston B, Clabots C *et al. Escherichia coli* sequence type ST131 as the major cause of serious multidrug-resistant *E. coli* infections in the United States. *Clin Infect Dis* 2010; **51**: 286–94.

25 Poulsen HO, Johansson A, Granholm S *et al*. High genetic diversity of nitrofurantoin- or mecillinam-resistant *Escherichia coli* indicates low propensity for clonal spread. *J Antimicrob Chemother* 2013; **68**: 1974–7.

26 Damiani G, Silvestrini G, Federico B *et al*. A systematic review on the effectiveness of group versus single-handed practice. *Health Policy* 2013; **113**: 180–7.

27 Sun L, Klein EY, Laxminarayan R. Seasonality and temporal correlation between community antibiotic use and resistance in the United States. *Clin Infect Dis* 2012; **55**: 687–94.

28 Gulliford MC, Dregan A, Moore MV *et al.* Continued high rates of antibiotic prescribing to adults with respiratory tract infection: survey of 568 UK general practices. *BMJ Open* 2014; **4**: e006245.

29 van der Eerden MM, Vlaspolder F *et al.* Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. *Thorax* 2005; **60**: 672–8.

30 Vellinga A, Tansey S, Hanahoe B *et al*. Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with *Escherichia coli*: a multilevel model. *J Antimicrob Chemother* 2012; **67**: 2523–30.

31 United Kingdom National External Quality Assessment Service (UK NEQAS). http://www.ukneqasmicro.org.uk/.